Why Soleno Therapeutics Stock Rocketed Higher on Monday
On news that Soleno Therapeutics (NASDAQ: SLNO) has agreed to be acquired, investors piled into the company's shares on Monday. This left the commercial-stage biotech with a juicy 32% gain on the day's trading session.
That morning, Soleno and its peer biotech, Neurocrine Biosciences (NASDAQ: NBIX), announced that they had signed a definitive agreement under which Neurocrine would acquire Soleno. The deal, valued at $2.9 billion, will see Neurocrine pay $53 per share in an all-cash transaction to own Soleno.
Image source: Getty Images.
Source Fool.com
Neurocrine Bioscience Aktie
151,80 €
-0,75 %
Uneingeschränkte Unterstützung für Neurocrine Bioscience, ausschließlich Buy-Einschätzungen.
Ein positives, wenn auch nicht starkes, Potenzial für Neurocrine Bioscience mit einem Kursziel von 154 € im Vergleich zu 151.8 €.
